Physician profile
Juzar Ali
NPI 1508887522
$215,850.33
in general payments reported to CMS, 2019-2025
14 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $42K · 2021: $5,600 · 2022: $10K · 2023: $28K · 2024: $16K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Travel and Lodging: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000 · Food and Beverage: $2,104 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,661.90 |
| Travel and Lodging | $10,046.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
| Food and Beverage | $2,103.63 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $157,274.04 | 2019-2025 | Arikayce, Brinsupri |
| Oxford Immunotec USA INC | $50,186.37 | 2019-2021 | |
| Zambon USA LTD. | $4,890.65 | 2024 | |
| Revvity, INC. | $3,000.00 | 2025 | |
| Electromed, INC. | $183.45 | 2019-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $131.66 | 2022 | |
| Abbott Laboratories | $90.49 | 2019 | |
| Baxter Healthcare | $25.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.60 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.39 | 2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Gilead Sciences, INC. | $14.06 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juzar Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.